AARD Latest Headlines

Aardvark Therapeutics advances ARD-101 after FDA hold lift

at www.tipranks.com (Fri, 23-Oct 9:28 AM)

Sell Rating Maintained on ARD-101 Amid Ongoing Clinical Uncertainty; $3 Price Target Reiterated Versus $4.41 Share Price

at www.tipranks.com (Fri, 23-Oct 6:35 AM)

FDA Lifts Clinical Hold on Aardvark’s ARD-101 Program

at www.tipranks.com (Thu, 22-Oct 4:52 PM)

Aardvark Therapeutics rises as a shareholder investigation spotlights ARD-101 safety claims and trial setbacks

Market Chameleon (Wed, 21-Oct 10:33 AM)

AARD lawsuit notice spotlights ARD-101 trial pause and FDA clinical hold, with an Oct. 13, 2026 lead-plaintiff deadline

Market Chameleon (Wed, 7-Oct 10:48 AM)

Robbins LLP investigation spotlights ARD-101 trial pause and FDA clinical hold at Aardvark Therapeutics (AARD)

Market Chameleon (Fri, 18-Sep 11:02 AM)

Aardvark Maintains Cash Runway Through 2027 Amid Clinical Program Pause and Strategic Assessment

Market Chameleon (Wed, 12-Aug 7:58 AM)